A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

RTHM-023422026Erritzoe, David; Barba, Tommaso; Benway, Tiffanie; Joel, Zelah; Good, Meghan; Layzell, Marie; Jones, Michelle Baker; Campbell, Graham; Murphy-Beiner, Ashleigh; Rands, Peter; Boyce, Malcolm; Topping, Helen; Weiss, Brandon; Timmermann, Christopher; Nutt, David; Carhart-Harris, Robin; Routledge, Carol; James, Ellen

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Nature medicine, 32(2), 591-598

View on PubMed ↗Publisher’s paper ↗

Citation

Erritzoe, David; Barba, Tommaso; Benway, Tiffanie; Joel, Zelah; Good, Meghan; Layzell, Marie; Jones, Michelle Baker; Campbell, Graham; Murphy-Beiner, Ashleigh; Rands, Peter; Boyce, Malcolm; Topping, Helen; Weiss, Brandon; Timmermann, Christopher; Nutt, David; Carhart-Harris, Robin; Routledge, Carol; James, Ellen. (2026). A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.. Nature medicine, 32(2), 591-598. https://doi.org/10.1038/s41591-025-04154-z